Methimazole

Limits on what this shows

• Key negative/null findings: The in vitro/in vivo study is explicitly described as "paradoxical," meaning it does not show a single, one-directional effect; this review could not obtain the full abstract (individual PubMed page returned a bot-verification challenge) to state the precise conditions under which mitochondrial effects are protective versus harmful.
• At-risk subgroups: Patients on methimazole who develop hepatotoxicity (a rare, already-labeled idiosyncratic reaction); pediatric patients, for whom the label notes elevated antithyroid-drug hepatotoxicity risk generally (more so for propylthiouracil).
• Counter-evidence on record: None identified suggesting methimazole damages mitochondria at ordinary therapeutic exposure in patients who do not develop hepatotoxicity; the mechanism appears specific to the idiosyncratic reaction, not a universal effect.

Regulatory status

The FDA label already carries a Tier A hepatotoxicity warning: discontinue if hepatic transaminases exceed 3× the upper limit of normal; risk is described as lower with methimazole than with propylthiouracil, especially in pediatric patients.

Population evidence

"Paradoxical effect of methimazole on liver mitochondria: In vitro and in vivo," Toxicol Lett 2016 (PMID 27506418): in vitro and in vivo hepatocyte mitochondrial studies using methimazole directly, describing context/exposure-dependent (paradoxical) effects on mitochondrial function. "Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave's disease: a metabolomic approach," Arch Toxicol 2020 (PMID 31740989): human, Graves' disease patients with methimazole-induced hepatotoxicity, metabolomic mechanism study.

Mechanism

Named but exposure-dependent: mitochondrial involvement in the idiosyncratic hepatotoxicity reaction already recognized in the label, rather than a dose-independent, universal mitochondrial-injury effect of therapeutic dosing.

Counter-evidence held on record

This is mechanistic evidence tied to a rare, already-labeled hepatotoxicity reaction, monitored by liver function tests per the label, not a general nutrient-style mitochondrial deficiency and not something addressed by antioxidant or mitochondrial-support supplementation.

Limits on what this shows

• Key negative/null findings: The human Tier A studies measured conjugated dienes, malondialdehyde, and Schiff bases specifically and found reductions, a genuine measured-marker finding, not an inference; this is the most useful null-for-depletion result in this category.
• At-risk subgroups: The harmful-direction findings are drawn from toxicological/high-concentration exposure models (in vitro cell lines, drug-induced hypothyroid rodent models) and are most relevant to the mechanism of the drug's rare, already-labeled hepatotoxicity and to overdose scenarios, not to ordinary therapeutic dosing in euthyroid-maintained patients.
• Counter-evidence on record: The two directions are not actually contradictory once exposure context is separated: therapeutic human dosing correlates with reduced oxidative markers as disease resolves, while supraphysiologic/toxic exposure in animal and cell models increases oxidative stress. Both are reported here rather than only the more favorable human data.

Regulatory status

Not addressed in the FDA label as an oxidative-stress claim.

Population evidence, therapeutic/human (protective direction)

"Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease," Endocr Regul 2000 (PMID 10911409): hyperthyroid Graves' disease patients, reduced conjugated dienes, malondialdehyde, and Schiff bases with treatment. "Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment," Clin Biochem 2005 (PMID 15607311): Graves' disease patients with and without eye involvement, improved oxidative-stress parameters with antithyroid treatment.

Population evidence, toxic/experimental exposure (harmful direction)

Quercetin-protection rat study, Exp Clin Endocrinol Diabetes 2014 (PMID 24918533), methimazole 20 mg/100 mL drinking water for one month inducing oxidative stress; breast-tissue study, Endocr Relat Cancer 2021 (PMID 34010147), methimazole-induced hypothyroidism in female Wistar rats (0.03% methimazole, 7-21 days) increasing ROS and DNA damage; Ann Hepatol 2010 (PMID 20308726), rat liver time-course showing methimazole-induced hypothyroidism alters the redox environment and causes hepatic damage; Vet Sci 2021 (PMID 34679050), feline kidney epithelial cell line, direct methimazole cytotoxicity/oxidative stress; Adv Pharm Bull 2023 (PMID 36721818), pancreatic cells exposed to 0-40 mM methimazole for 48 hours, elevated total oxidant status and reduced antioxidant capacity; Eur J Pharmacol 2016 (PMID 27568837), isolated pancreatic islets from methimazole-induced hypothyroid rats, induction of oxidative stress alongside suppressed ATP production (see ATP production entry and Overlap map).

Mechanism

At therapeutic human dosing, the reduction in oxidative markers plausibly reflects correction of the hyperthyroid hypermetabolic state itself (confounding by indication) rather than a direct antioxidant action of the drug; at high/toxic in vitro and in vivo exposure, direct cytotoxic and redox-disrupting effects on hepatic, pancreatic, and renal cell models are documented.

Counter-evidence held on record

Do not use the human protective-direction data to market antioxidant supplementation as necessary for methimazole users, and do not use the toxicological data to claim ordinary therapeutic dosing causes oxidative injury. Direction depends on exposure level and disease state, not a fixed drug effect.

Limits on what this shows

• Key negative/null findings: In the Alturfan et al. study, glutathione (GSH) and superoxide dismutase (SOD) levels were reported unchanged even as copper, zinc, and 3-nitrotyrosine fell, indicating the effect is not a generalized antioxidant-enzyme disruption.
• At-risk subgroups: None established. No human dosing or exposure threshold at which copper chelation becomes clinically relevant has been studied.
• Counter-evidence on record: None found contradicting the in vitro chelation finding. The limiting factor is the complete absence of a human clinical copper-status study with methimazole in the cohort, not conflicting data. Two additional PubMed results for "methimazole copper" (an electrochemical sensor using a copper/graphene-oxide nanocomposite to detect methimazole in samples, and a copper-nanocluster fluorescent probe for methimazole detection) are analytical-chemistry detection methods, not biological or pharmacological studies, and are excluded from this entry's evidence base as irrelevant to drug-nutrient status.

Regulatory status

Not addressed in the FDA label.

Population evidence

Hanlon DP, Shuman S. "Copper ion binding and enzyme inhibitory properties of the antithyroid drug methimazole." Experientia. 1975;31(9):1005-1006. PMID 809293, DOI 10.1007/bf02326924. In vitro biochemistry, methimazole used directly; reports direct copper-ion binding and slight inhibition of ceruloplasmin oxidase activity. Urquiza NM et al. "Copper(II) complexes of methimazole, an anti Grave's disease drug. Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor." Biometals. 2010. PMID 20012553, DOI 10.1007/s10534-009-9283-7. In vitro coordination chemistry, methimazole used directly. Urquiza NM et al. "Anti-thyroid and antifungal activities, BSA interaction and acid phosphatase inhibition of methimazole copper(II) complexes." Chem Biol Interact. 2015. PMID 25641192. In vitro, methimazole used directly. Li Y et al. "Elucidating the Protective Mechanisms of Methimazole against Copper(I)-Mediated Fenton Chemistry Using Online Mass Spectrometry." J Am Soc Mass Spectrom. 2025. PMID 41163555. In vitro mass-spectrometry chemistry, methimazole used directly. Alturfan AA et al. "Investigation of Zinc and Copper Levels in Methimazole-Induced Hypothyroidism: Relation with the Oxidant-Antioxidant Status." Folia Biol (Praha). 2007. PMID 17976309. Reports significantly decreased 3-nitrotyrosine, copper, and zinc levels versus controls under methimazole-induced hypothyroidism; this review could not independently confirm whether the study population was human or an animal model (the phrase "methimazole-induced hypothyroidism" matches the rat-model convention used elsewhere in this dossier's Oxidative stress entry, but species was not confirmed from the sources this review could access), so it is treated as Tier B.

Mechanism

Named: methimazole's thioamide/thiourea sulfur chemistry binds copper(I) and copper(II) ions directly, demonstrated by isolated coordination-complex synthesis and characterization and by protection against copper(I)-catalyzed Fenton chemistry in mass-spectrometry experiments. This is a direct chelation mechanism, not an absorption-interference or catabolic mechanism, and is mechanistically distinct from methimazole's thyroid peroxidase inhibition.

Counter-evidence held on record

This is in vitro and mechanistic chemistry evidence, not a demonstrated clinical copper deficiency. Do not present methimazole as causing clinically meaningful copper loss, and do not use this entry to justify copper supplementation or routine copper testing without a specific clinical indication.

Limits on what this shows

• Key negative/null findings: A separate case report already cited in this dossier (Ren Fail 2007, PMID 17763175, hyperthyroidism-associated erythropoietin resistance) explicitly ruled out iron deficiency and megaloblastic anemia by laboratory testing as the cause of that patient's findings, a genuine negative result against a simple "methimazole causes iron deficiency" narrative.
• At-risk subgroups: Newly diagnosed or inadequately treated hyperthyroid Graves' disease patients with concurrent anemia at presentation, per the case-report literature.
• Counter-evidence on record: The Ren Fail 2007 case report's explicit exclusion of iron deficiency is counter-evidence against a depletion narrative. No study comparing methimazole-treated to untreated hyperthyroid patients was located that would isolate a drug-specific, as opposed to disease-state, iron effect.

Regulatory status

Not addressed in the FDA label.

Population evidence

Zwirska-Korczala K, Buntner B, Sobieraj H, Ostrowska Z, Kniazewski B, Swietochowska E. "Serum ferritin, iron and transferrin in women with thyrotoxic Graves' disease before and after methimazole treatment." Acta Physiol Pol. 1990. PMID 2136311. Human, n=47 women, before/after methimazole-treatment design, directly measuring serum iron, ferritin, and transferrin. This review located the study's existence, cohort, and design through a PubMed search-listing summary but could not open the underlying 1990 Acta Physiologica Polonica article (a discontinued, pre-DOI-era Polish journal) through PubMed's individual abstract page, Europe PMC, Semantic Scholar, or Crossref bibliographic search, so the direction and magnitude of the pre/post change are not independently confirmed by this review. Daldal F, Dancis A. "Graves' Disease and Microcytic Anemia: A Forgotten Connection." Am J Case Rep. 2024. PMID 39587452. Single case report, methimazole-treated, reporting that ferritin decreased over the course of treatment. This is the same underlying case already cited under Oxygen delivery/utilization above for its erythropoietin/anemia findings; the ferritin observation here is drawn from that same single case, not independent confirmation.

Mechanism

Not a classical drug-depletion mechanism. Thyroid hormone is known to influence ferritin synthesis and iron turnover, and hyperthyroidism itself is associated with disturbed iron indices in the general literature; methimazole's role in any observed ferritin change is more plausibly disease-state correction (treating hyperthyroidism) than a direct drug effect on iron absorption, transport, or storage, but this review could not confirm which direction the 1990 cohort study moved to test that interpretation.

Counter-evidence held on record

Human iron-parameter data exist for methimazole-treated patients, but this review could not confirm whether treatment raised, lowered, or left iron status unchanged, and a companion case report explicitly ruled out iron deficiency in a similar clinical picture. Do not present this as an established iron-depletion or iron-benefit effect, and do not use it to justify iron supplementation or routine iron testing based on methimazole use alone.

Limits on what this shows

• Key negative/null findings: None of the sources located directly separates a drug-specific microbiome effect from a disease-correction effect in a controlled design (e.g., comparing methimazole-treated patients to untreated hyperthyroid patients over the same interval).
• At-risk subgroups: Newly diagnosed Graves' disease patients around treatment initiation, as studied in the cited human and adjunct-therapy trials.
• Counter-evidence on record: Confounding by indication is presumed and not excluded here: this review found no study comparing microbiome change in methimazole-treated versus untreated (or alternative-treatment) hyperthyroid patients that would isolate the drug's own contribution.

Regulatory status

Not addressed in the FDA label.

Population evidence, human

A study observing changes in intestinal flora composition in Graves' disease patients before and after methimazole treatment, Front Cell Infect Microbiol 2022 (PMID 35402292). This is a Tier A candidate (human, methimazole directly in the cohort, observational pre/post design), but this review could not open the individual PubMed abstract page (bot-verification challenge) to confirm sample size or effect estimate; only the title and a synthesized search-listing summary were available, which is why this is graded yellow rather than orange.

Population evidence, mechanistic/animal and adjunct-therapy

"Gut Microbiota Participates in Antithyroid Drug Induced Liver Injury Through the Lipopolysaccharide Related Signaling Pathway," Front Pharmacol 2020 (PMID 33390986; abstract page also blocked during this review, species/cohort not independently confirmed beyond the title). "Gut microbiota alteration was related to subclinical hypothyroidism and dyslipidemia in mice," FASEB J 2025 (PMID 40052844), methimazole used to induce the mouse model. "Probiotic Bifidobacterium longum supplied with methimazole improved the thyroid function of Graves' disease patients through the gut-thyroid axis," Commun Biol 2021 (PMID 34493790). "The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal Microbiome," Front Immunol 2022 (PMID 35082799). "Bacteroides fragilis and propionate synergize with low-dose methimazole to treat Graves' disease," Microbiol Spectr 2025 (PMID 40265938).

Mechanism

Plausible but not fully isolated from disease-state correction: both the treated disease (Graves' hyperthyroidism, itself associated with altered gut flora in some literature) and the drug's own pharmacology could independently affect microbial composition; the adjunct-therapy trials (probiotic, prebiotic) demonstrate the axis is bidirectionally active, not that methimazole alone disrupts it.

Counter-evidence held on record

This is an active, genuine research area for methimazole specifically, not a settled drug-caused dysbiosis claim. Probiotic or prebiotic use for this purpose should be discussed with a prescriber, not self-directed from this entry.

Limits on what this shows

• Key negative/null findings: This review found no evidence, in the sources it could access, that methimazole itself reduces hemoglobin, hematocrit, or oxygen-carrying capacity outside of its rare, separately-labeled bone-marrow suppression/aplastic-anemia adverse reaction (an idiosyncratic immune-mediated event, not a nutrient mechanism).
• At-risk subgroups: Patients with untreated or inadequately treated hyperthyroidism and coexisting anemia; case-report-level evidence limits generalization.
• Counter-evidence on record: Case reports are individually weak evidence (Tier B) and the improvement described could reflect regression to the mean or concurrent iron/other therapy rather than methimazole specifically; this is disclosed rather than overstated.

Regulatory status

Not addressed in the FDA label as an oxygen-delivery claim; the label's mechanism-of-action section establishes that methimazole treats hyperthyroidism, the condition responsible for the hypermetabolic state described here.

Population evidence

"Graves' Disease and Microcytic Anemia: A Forgotten Connection," Am J Case Rep 2024 (PMID 39587452): single case, hyperthyroidism with concurrent microcytic anemia, treated with methimazole, with biochemical improvement. "An Unusual Etiology of Erythropoietin Resistance: Hyperthyroidism," Ren Fail 2007 (PMID 17763175): case report describing hyperthyroidism-associated erythropoietin resistance, with iron deficiency and megaloblastic anemia specifically ruled out by laboratory testing.

Mechanism

Two distinct, both non-deficiency mechanisms: (1) hyperthyroidism increases basal metabolic rate, oxygen consumption, and cardiac output; methimazole's reduction of these toward normal is the drug's own intended effect, per Hard Rule 2, and must not be filed as an oxygen-delivery deficiency. (2) Hyperthyroidism can independently impair erythropoietin responsiveness and red-cell parameters; treating the underlying thyroid state with methimazole is reported to improve these, a disease-reversal finding, not a drug-supplied nutrient effect.

Counter-evidence held on record

This is not an oxygen-delivery deficiency caused by methimazole. It is the drug's own intended reduction of hyperthyroid metabolic overdrive, plus case-report evidence that treating the underlying disease can improve disease-associated anemia. Never market this as methimazole supporting oxygen delivery or as a reason to supplement.

Limits on what this shows

• Key negative/null findings: This is a single animal study in a drug-induced hypothyroid model (i.e., an overtreatment/experimental state), not a euthyroid-maintained therapeutic-dosing model; no human ATP-production data for methimazole were located.
• At-risk subgroups: Not established in humans; theoretically most relevant to iatrogenic overtreatment producing sustained hypothyroidism, which is managed by TSH-guided dose titration, not supplementation.
• Counter-evidence on record: None identified; the limiting factor is that this finding has not been replicated in humans or at therapeutic (non-hypothyroid-inducing) exposure.

Regulatory status

Not addressed in the FDA label.

Population evidence

"Induction of oxidative stress, suppression of glucose-induced insulin release, ATP production, glucokinase activity...," Eur J Pharmacol 2016 (PMID 27568837): isolated pancreatic islets from methimazole-treated hypothyroid rats, with ATP production, glucokinase activity, and glucose-induced insulin release all suppressed and oxidative stress induced in the same experiment (see Overlap map).

Mechanism

Named: drug-induced hypothyroidism impairing islet mitochondrial bioenergetics and glucose-sensing machinery, studied in an animal model specifically induced with methimazole.

Counter-evidence held on record

Animal, drug-induced-hypothyroidism model only. Do not extrapolate to a general "methimazole lowers ATP" claim for patients maintained at a euthyroid dose, and do not use this to justify a mitochondrial-support or energy-supplement recommendation.